{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:21:50Z","timestamp":1790004110309,"version":"4.0.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T00:00:00Z","timestamp":1417737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Targeted ERBB2\/HER2 inhibitors are approved by the U.S. Food and Drug Administration for the treatment of breast, gastric, and esophageal cancers that overexpress or amplify HER2\/ERBB2, as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively. Activating mutations in ERBB2 have also been reported and are predicted to confer sensitivity to these targeted agents. Testing for these mutations is not performed routinely, and FISH and IHC are not applied outside of these approved indications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods.<\/jats:title>\n                  <jats:p>We explored the spectrum of activating ERBB2 alterations across a collection of \u223c7,300 solid tumor specimens that underwent comprehensive genomic profiling using next-generation sequencing. Results were analyzed for base substitutions, insertions and deletions, select rearrangements, and copy number changes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Known oncogenic ERBB2 alterations were identified in tumors derived from 27 tissues, and ERBB2 amplification in breast, gastric, and gastroesophageal cancers accounted for only 30% of these alterations. Activating mutations in ERBB2 were identified in 131 samples (32.5%); amplification was observed in 246 samples (61%). Two samples (0.5%) harbored an ERBB2 rearrangement. Ten samples (2.5%) harbored multiple ERBB2 mutations, yet mutations and amplifications were mutually exclusive in 91% of mutated cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Standard slide-based tests for overexpression or amplification of ERBB2 would fail to detect the majority of activating mutations that occur overwhelmingly in the absence of copy number changes. Compared with current clinical standards, comprehensive genomic profiling of a more diverse set of tumor types may identify \u223c3.5 times the number of patients who may benefit from ERBB2-targeted therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0234","type":"journal-article","created":{"date-parts":[[2014,12,6]],"date-time":"2014-12-06T06:32:43Z","timestamp":1417847563000},"page":"7-12","source":"Crossref","is-referenced-by-count":87,"title":["Oncogenic Alterations in <i>ERBB2\/HER2<\/i> Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin"],"prefix":"10.1093","volume":"20","author":[{"given":"Juliann","family":"Chmielecki","sequence":"first","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"},{"name":"Department of Pathology, Albany Medical College, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett M.","family":"Frampton","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Palmer","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj M.","family":"Ali","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Palma","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Morosini","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Yelensky","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Lipson","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Cambridge, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,12,5]]},"reference":[{"key":"2021122309224638600_B1","volume-title":"Committee on A Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease","author":"National Research Council (U.S.)","year":"2011"},{"key":"2021122309224638600_B2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-med-060712-200152","article-title":"DNA sequencing of cancer: What have we learned?","volume":"65","author":"Chmielecki","year":"2014","journal-title":"Annu Rev Med"},{"key":"2021122309224638600_B3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1126\/science.1073096","article-title":"Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer","volume":"297","author":"Weinstein","year":"2002","journal-title":"Science"},{"key":"2021122309224638600_B4","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309224638600_B5","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122309224638600_B6","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122309224638600_B7","doi-asserted-by":"crossref","first-page":"127rv2","DOI":"10.1126\/scitranslmed.3001539","article-title":"Improving treatment of HER2-positive cancers: Opportunities and challenges","volume":"4","author":"Stern","year":"2012","journal-title":"Sci Transl Med"},{"key":"2021122309224638600_B8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122309224638600_B9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122309224638600_B10","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122309224638600_B11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"2021122309224638600_B12","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122309224638600_B13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mds284","article-title":"Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy","volume":"24","author":"Awada","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122309224638600_B14","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazi\u00e8res","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309224638600_B15","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.5858\/2008-132-1008-TAATFE","article-title":"Trastuzumab as adjuvant therapy for early breast cancer: The importance of accurate human epidermal growth factor receptor 2 testing","volume":"132","author":"Hicks","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"2021122309224638600_B16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","article-title":"HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing","volume":"457","author":"R\u00fcschoff","year":"2010","journal-title":"Virchows Arch"},{"key":"2021122309224638600_B17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: Biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"2021122309224638600_B18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/431525b","article-title":"Lung cancer: Intragenic ERBB2 kinase mutations in tumours","volume":"431","author":"Stephens","year":"2004","journal-title":"Nature"},{"key":"2021122309224638600_B19","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","article-title":"Somatic mutations of the HER2 kinase domain in lung adenocarcinomas","volume":"65","author":"Shigematsu","year":"2005","journal-title":"Cancer Res"},{"key":"2021122309224638600_B20","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/ijc.22143","article-title":"Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features","volume":"119","author":"Buttitta","year":"2006","journal-title":"Int J Cancer"},{"key":"2021122309224638600_B21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov"},{"key":"2021122309224638600_B22","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1158\/1078-0432.CCR-13-0295","article-title":"Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations","volume":"19","author":"Ross","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122309224638600_B23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122309224638600_B24","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.1203201109","article-title":"Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2","volume":"109","author":"Greulich","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309224638600_B25","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/0008-5472.CAN-06-0971","article-title":"Non-small-cell lung cancer and Ba\/F3 transformed cells harboring the ERBB2 G776insV_G\/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272","volume":"66","author":"Shimamura","year":"2006","journal-title":"Cancer Res"},{"key":"2021122309224638600_B26","doi-asserted-by":"crossref","first-page":"e26760","DOI":"10.1371\/journal.pone.0026760","article-title":"Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib","volume":"6","author":"Kancha","year":"2011","journal-title":"PLoS One"},{"key":"2021122309224638600_B27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12032-011-9884-1","article-title":"Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: Case report and literature review","volume":"29","author":"Kaidar-Person","year":"2012","journal-title":"Med Oncol"},{"key":"2021122309224638600_B28","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc060020","article-title":"HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer","volume":"354","author":"Cappuzzo","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122309224638600_B29","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1200\/JCO.2013.49.0599","article-title":"Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy","volume":"32","author":"Ali","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309224638600_B30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2021122309224638600_B31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"key":"2021122309224638600_B32","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/1078-0432.CCR-07-4367","article-title":"EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation","volume":"14","author":"Trowe","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122309224638600_B33","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1038\/sj.onc.1210292","article-title":"The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR\/ERBB2 inhibitor HKI-272","volume":"26","author":"Minami","year":"2007","journal-title":"Oncogene"},{"key":"2021122309224638600_B34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2006.05.023","article-title":"HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors","volume":"10","author":"Wang","year":"2006","journal-title":"Cancer Cell"},{"key":"2021122309224638600_B35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/modpathol.2013.135","article-title":"Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy","volume":"27","author":"Ross","year":"2014","journal-title":"Mod Pathol"},{"key":"2021122309224638600_B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2012.09.008","article-title":"Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors","volume":"22","author":"Nielsen","year":"2013","journal-title":"Breast"},{"key":"2021122309224638600_B37","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/CAD.0b013e328352d292","article-title":"Recent advances in novel targeted therapies for HER2-positive breast cancer","volume":"23","author":"Murphy","year":"2012","journal-title":"Anticancer Drugs"},{"key":"2021122309224638600_B38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrgastro.2011.81","article-title":"Anti-HER agents in gastric cancer: From bench to bedside","volume":"8","author":"Fornaro","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2021122309224638600_B39","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122309224638600_B40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1158\/1078-0432.CCR-05-0976","article-title":"Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas","volume":"12","author":"Lee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309224638600_B41","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2021122309224638600_B42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2021122309224638600_B43","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2021122309224638600_B44","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/1471-2407-10-376","article-title":"Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas","volume":"10","author":"Liang","year":"2010","journal-title":"BMC Cancer"},{"key":"2021122309224638600_B45","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1634\/theoncologist.2014-0054","article-title":"Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F","volume":"19","author":"Vornicova","year":"2014","journal-title":"The Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0234","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0234","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/1\/7\/41867977\/oncolo_20_1_7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/1\/7\/41867977\/oncolo_20_1_7.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:14:42Z","timestamp":1640312082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/1\/7\/6399246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12,5]]},"published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0234","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,1,1]]},"published":{"date-parts":[[2014,12,5]]}}}